[go: up one dir, main page]

DK1266006T3 - Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier - Google Patents

Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier

Info

Publication number
DK1266006T3
DK1266006T3 DK01927769T DK01927769T DK1266006T3 DK 1266006 T3 DK1266006 T3 DK 1266006T3 DK 01927769 T DK01927769 T DK 01927769T DK 01927769 T DK01927769 T DK 01927769T DK 1266006 T3 DK1266006 T3 DK 1266006T3
Authority
DK
Denmark
Prior art keywords
factor viii
human cell
muteins
factor
promoter
Prior art date
Application number
DK01927769T
Other languages
English (en)
Inventor
Charlotte Hauser
Andrea Hoerster
Carola Schroeder
Michael Lehnerer
Original Assignee
Octagene Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00106225A external-priority patent/EP1136553A1/en
Application filed by Octagene Gmbh filed Critical Octagene Gmbh
Application granted granted Critical
Publication of DK1266006T3 publication Critical patent/DK1266006T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
DK01927769T 2000-03-22 2001-03-21 Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier DK1266006T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00106225A EP1136553A1 (en) 2000-03-22 2000-03-22 Production of recombinant blood clotting factors in human cell lines
US20324900P 2000-05-08 2000-05-08

Publications (1)

Publication Number Publication Date
DK1266006T3 true DK1266006T3 (da) 2006-01-16

Family

ID=26070708

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01927769T DK1266006T3 (da) 2000-03-22 2001-03-21 Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier

Country Status (28)

Country Link
US (1) US7572619B2 (da)
EP (2) EP1460131A3 (da)
JP (1) JP3894795B2 (da)
KR (1) KR100581574B1 (da)
CN (1) CN1454257B (da)
AT (1) ATE312176T1 (da)
AU (3) AU5471501A (da)
BE (1) BE2014C077I2 (da)
BG (1) BG65930B1 (da)
BR (1) BRPI0109494B8 (da)
CA (1) CA2404163C (da)
CZ (1) CZ303929B6 (da)
DE (1) DE60115613T2 (da)
DK (1) DK1266006T3 (da)
EA (1) EA004317B1 (da)
EE (1) EE200200538A (da)
ES (1) ES2254403T3 (da)
FR (1) FR15C0003I2 (da)
HR (1) HRP20020767B1 (da)
HU (1) HU228091B1 (da)
IL (2) IL151857A0 (da)
MX (1) MXPA02009221A (da)
NO (1) NO330910B1 (da)
NZ (1) NZ521732A (da)
RS (1) RS50743B (da)
SI (1) SI1266006T1 (da)
SK (1) SK287706B6 (da)
WO (1) WO2001070968A2 (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287706B6 (en) * 2000-03-22 2011-07-06 Octapharma Biopharmaceuticals Gmbh Production of recombinant blood clotting factors in human cell lines
MXPA03002256A (es) * 2000-09-19 2003-09-10 Univ Emory Factor viii modificado.
EP1469064A1 (en) 2003-04-15 2004-10-20 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Expression of proteins in endothelial cells derived from precursor cells from cord blood
DE602005024955D1 (de) 2004-03-19 2011-01-05 Baxter Healthcare Sa Faktor ixa zur behandlung von blutungsstörungen
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
ATE549037T1 (de) 2004-09-22 2012-03-15 St Jude Childrens Res Hospital Verbesserte expression von faktor-ix in gentherapie-vektoren
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP1851305B1 (en) * 2005-02-11 2012-01-18 Novo Nordisk Health Care AG Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
CN101541950A (zh) 2006-07-13 2009-09-23 惠氏公司 糖蛋白的产生
CA3090908A1 (en) * 2007-04-26 2008-11-06 Aptevo Biotherapeutics Llc Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
EP2198870A4 (en) * 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp ACTIVATOR FOR BLOOD CREATION FACTOR VII PROMOTER AND ITS USE
CA2732423A1 (en) 2008-08-21 2010-02-25 Octapharma Ag Recombinantly produced human factor viii and ix
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
PT2482841T (pt) 2009-10-02 2019-03-01 Childrens Hospital Philadelphia A presente invenção refere-se à utilização de lactonas macrocíclicas para o tratamento da demodicose, em particular em cães.
EP3421491A3 (en) 2009-10-30 2019-03-27 Albumedix Ltd Albumin variants
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
BRPI1105317A2 (pt) 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
CN102199607B (zh) * 2011-03-30 2012-11-14 山西大学 重组人凝血因子ix小基因及其ptc突变体稳定细胞株
ES2970057T3 (es) 2011-05-13 2024-05-24 Octapharma Ag Un procedimiento para aumentar la productividad de células eucarióticas en la producción de FVIII recombinante
TW201307563A (zh) * 2011-05-19 2013-02-16 Shire Human Genetic Therapies 純化乙醯肝素－ｎ－硫酸酯酶之方法
BR112013032630B1 (pt) 2011-06-30 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Polipeptídeo heterodimerizado compreendendo região fc de igg
CN102321668A (zh) * 2011-07-06 2012-01-18 中国人民解放军军事医学科学院野战输血研究所 一种表达重组人凝血因子ⅶ的方法及其专用载体
EP2762493B1 (en) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CN103917554B (zh) 2011-10-18 2017-03-08 杰特有限公司 用于改善重构后纯化的因子viii的稳定性的方法
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
EP3517550A1 (en) 2011-11-30 2019-07-31 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
JP6441682B2 (ja) 2012-03-16 2018-12-19 アルブミディクス リミティド アルブミン変種
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
WO2014008172A2 (en) * 2012-07-03 2014-01-09 Expression Therapeutics, Llc High yield suspension cell line, system and method for making same
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
CN105452290A (zh) 2012-11-08 2016-03-30 诺维信生物制药丹麦公司 白蛋白变体
US20150352194A1 (en) * 2013-01-24 2015-12-10 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
CA2908350C (en) 2013-04-02 2023-08-08 Futa Mimoto Fc region variant
EP2853538A1 (en) 2013-09-27 2015-04-01 Université Pierre et Marie Curie (Paris 6) Analogues of temporin-SHa and uses thereof
PE20170771A1 (es) * 2014-07-30 2017-07-04 Ngm Biopharmaceuticals Inc Composiciones y metodos de uso para tratar trastornos metabolicos
EA036985B1 (ru) 2014-10-31 2021-01-25 НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК. Композиции и способы лечения метаболических расстройств
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
AR104956A1 (es) 2015-06-09 2017-08-30 Glycotope Gmbh MÉTODO MEJORADO PARA LA PRODUCCIÓN DE POLIPÉPTIDOS g-CARBOXILADOS
BR112018003179A2 (pt) 2015-08-20 2018-09-25 Albumedix As conjugados e variantes de albumina
CN105219739A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR102450833B1 (ko) 2016-04-15 2022-10-05 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 혈우병 a 치료용 유전자 요법
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018210771A1 (en) 2017-05-17 2018-11-22 Octapharma Ag Method for the production of a recombinant target protein
JP7731196B2 (ja) 2017-11-14 2025-08-29 中外製薬株式会社 抗Ｃ１ｓ抗体および使用方法
WO2020020364A1 (zh) * 2018-07-26 2020-01-30 正大天晴药业集团南京顺欣制药有限公司 一种制备重组人凝血因子ⅷ的方法
AU2019318031B2 (en) 2018-08-10 2025-06-05 Chugai Seiyaku Kabushiki Kaisha Anti-CD137 antigen-binding molecule and utilization thereof
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
CN120865384A (zh) 2018-10-23 2025-10-31 费城儿童医院 用于调节因子viii功能的组合物和方法
KR20220016865A9 (ko) 2019-05-15 2022-02-21 추가이 세이야쿠 가부시키가이샤 항원 결합 분자, 약학 조성물, 및 방법
CA3221235A1 (en) 2021-06-11 2022-12-15 Ali Ladram Short antimicrobial peptides

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI86885C (fi) * 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
JPS6171774A (ja) * 1984-09-14 1986-04-12 Sony Corp テレビジヨンカメラ装置のビ−ム電流制御装置
EP0218713B1 (en) * 1985-04-22 1992-03-25 Genetics Institute, Inc. High yield production of active factor ix
DE3785102T2 (de) * 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5024939A (en) 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
FI922204A0 (fi) * 1989-11-17 1992-05-14 Novo Nordisk As Proteinkomplex med faktor viii:c- aktivitet och framstaellning av desamma.
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
ES2052368T3 (es) * 1990-01-26 1994-07-01 Immuno Ag Factores sanguineos producidos por recombinacion y el proceso para la expresion de dichos factores, asi como recombinacion del virus de vaccina usados en dicho proceso.
US5445953A (en) * 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
JPH08511423A (ja) * 1993-06-10 1996-12-03 ジェネティック セラピー，インコーポレイテッド 血友病治療のためのアデノウイルスベクター
EP0951544A2 (en) * 1996-07-03 1999-10-27 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of human disease
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
CA2312291A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
CA2362970A1 (en) * 1999-02-19 2000-08-24 Octagene Gmbh Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy
WO2001012836A1 (en) * 1999-08-13 2001-02-22 Fred Hutchinson Cancer Research Center Crystal of a truncated protein construct containing a coagulation factor viii c2 domain in the presence or absence of a bound ligand and methods of use thereof
SK287706B6 (en) * 2000-03-22 2011-07-06 Octapharma Biopharmaceuticals Gmbh Production of recombinant blood clotting factors in human cell lines
WO2003009237A1 (en) * 2001-07-18 2003-01-30 Skaginn Hf. A method and apparatus for relating information of a processed object to an operator

Also Published As

Publication number Publication date
EP1460131A3 (en) 2005-06-01
EE200200538A (et) 2004-04-15
WO2001070968A3 (en) 2001-12-13
BR0109494A (pt) 2002-12-10
HUP0300588A3 (en) 2005-09-28
FR15C0003I2 (fr) 2015-11-20
BRPI0109494B1 (pt) 2021-05-11
SK287706B6 (en) 2011-07-06
CA2404163A1 (en) 2001-09-27
US7572619B2 (en) 2009-08-11
SK15042002A3 (sk) 2003-09-11
HU228091B1 (en) 2012-10-29
WO2001070968A2 (en) 2001-09-27
NO20024475D0 (no) 2002-09-19
HUP0300588A2 (hu) 2003-06-28
JP2003530093A (ja) 2003-10-14
KR20030011079A (ko) 2003-02-06
IL151857A (en) 2010-05-31
HRP20020767B1 (hr) 2011-09-30
DE60115613T2 (de) 2006-08-24
NO20024475L (no) 2002-11-20
KR100581574B1 (ko) 2006-05-22
HRP20020767A2 (en) 2005-02-28
AU2001254715B2 (en) 2006-02-02
BG107152A (bg) 2003-06-30
RS50743B (sr) 2010-08-31
YU71002A (sh) 2005-11-28
CN1454257A (zh) 2003-11-05
US20040023333A1 (en) 2004-02-05
EP1460131A2 (en) 2004-09-22
CZ303929B6 (cs) 2013-07-03
AU5471501A (en) 2001-10-03
NZ521732A (en) 2004-05-28
BRPI0109494B8 (pt) 2021-05-25
CN1454257B (zh) 2013-01-16
CA2404163C (en) 2009-09-29
DE60115613D1 (de) 2006-01-12
EA004317B1 (ru) 2004-02-26
CZ20023166A3 (cs) 2003-02-12
SI1266006T1 (sl) 2006-06-30
NO330910B1 (no) 2011-08-15
MXPA02009221A (es) 2005-07-25
EP1266006B1 (en) 2005-12-07
BG65930B1 (bg) 2010-05-31
BE2014C077I2 (da) 2020-01-30
JP3894795B2 (ja) 2007-03-22
EA200201008A1 (ru) 2003-02-27
ES2254403T3 (es) 2006-06-16
EP1266006A2 (en) 2002-12-18
AU2006201848A1 (en) 2006-05-25
FR15C0003I1 (fr) 2015-02-27
IL151857A0 (en) 2003-04-10
ATE312176T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
DK1266006T3 (da) Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier
Yoshida et al. Peripheral blood mononuclear cells enhance the anabolic effects of platelet‐rich plasma on anterior cruciate ligament fibroblasts
ATE486614T1 (de) Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
DE502004012225D1 (de) Generierung künstlicher bindungsproteine auf der grundlage von ubiquitin-proteinen
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
ATE453669T1 (de) Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen
RU2007105677A (ru) Модифицированные витамин к-зависимые полипептиды
ATE532858T1 (de) Menschliche gerinnungsfaktor-vii-polypeptide
ATE320277T1 (de) Zusammensetzung und verfahren zur reparatur und regenerierung von knorpel und anderen geweben
ATE510912T1 (de) Zusammensetzungen und verfahren zur verbesserten expression von immunglobulinen von einem einzigen vektor unter verwendung einer peptidschnittstelle
ATE485371T1 (de) Varianten des menschlichen koagulationsfaktors vii
ATE451835T1 (de) Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
JP2010280682A (ja) フラビウイルス融合インヒビター
AR037038A1 (es) Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto
FR2857267B1 (fr) Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
ATE513033T1 (de) Expression von proteinen in aus nabelschnurblut gewonnenen endothelzellen
DK175989D0 (da) Fremgangsmaade til fremstilling af protein
DE602004028239D1 (de) Protease, für die protease codierende dna und verfahren zur herstellung der protease
EP1679372A4 (en) NEW PLEXIN POLYPEPTIDE, THIS CODING DNA AND USE THEREOF
ES2312228A1 (es) Epidermis cultivada secretora de factores terapeuticos producida por celulas madre de pelo y metodo de obtencion.